A phase 2 cooperative group adjuvant trial using a biomarker‐based decision algorithm in patients with stage I non‐small cell lung cancer (SWOG‐0720, NCT00792701)

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|15|2343-2351

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.15, 2014-08, pp. : 2343-2351

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

By  

CANCER, Vol. 121, Iss. 13, 2015-07 ,pp. : 2253-2261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of the radical hypofractioned radiotherapy treatment in patients with stage I and II of non-small cell lung cancer

By  

Journal of Radiotherapy in Practice, Vol. 12, Iss. 2, 2012-05 ,pp. : 139-145

Cambridge University Press

Access to resources Recommend Favorite

Radiofrequency ablation of stage IA non–small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3491-3498

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-05 ,pp. : 357-362

Karger

Access to resources Recommend Favorite